Nanobiotix SA NBTX.OQ, NBTX.O is expected to report results on April 2 for the period ending June 30 2024
LSEG's mean analyst estimate for Nanobiotix SA is for a loss of 36 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is "Buy".
Wall Street's median 12-month price target for Nanobiotix SA is $8.65, above its last closing price of $3.61.
This summary was machine generated March 31 at 14:02 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.